Michael V Walsh

Title: The Innovations of Michael V Walsh: A Pioneer in Sustained Release Dosage Forms

Introduction: Michael V Walsh, an accomplished inventor based in Westerville, Ohio, has made significant contributions to the field of pharmaceuticals with his inventive solutions. With a total of two patents to his name, Walsh's work primarily focuses on advanced drug delivery systems that enhance patient care and treatment options.

Latest Patents: Walsh's latest innovation is the "Sustained Release Dosage Form Unit Having Latex Coating and Method of Making the Same." This dosage form unit is designed to deliver one or more beneficial agents, such as a liquid enteral nutritional product. The core of the dosage form unit contains at least one beneficial agent, preferably a marker dye, which is dispersible in the fluid. Additionally, it includes a compatible binding agent that unifies the beneficial agents, and may also consist of components such as plasticizers, flow agents, lubricants, and hydrophilic agents. Encased in a latex coating, the dosage unit is crafted from a mixture that incorporates a hydrophobic base material, typically made from cellulose acetate microspheres. This coating is designed to form a matrix-type membrane, incorporating hydrophilic components that enable immediate release of the beneficial agent. Furthermore, a comprehensive method for producing this innovative dosage form is also detailed in the patent.

Career Highlights: Michael V Walsh holds a prominent role at Abbott Laboratories Corporation, where he continues to leverage his expertise in pharmaceutical sciences to drive innovation. His work has been instrumental in developing formulations that not only improve drug efficacy but also enhance patient compliance and safety.

Collaborations: Throughout his career, Walsh has collaborated with notable colleagues, including Terrence B Mazer and Joseph E Walton. These partnerships have yielded valuable insights and advancements in the field, enabling the development of effective drug delivery mechanisms that have the potential to transform patient treatment protocols.

Conclusion: Michael V Walsh's inventive contributions to sustained release dosage forms underscore his commitment to improving healthcare outcomes. His patents reflect a deep understanding of pharmaceutical formulations and innovative thinking, positioning him as a key figure at Abbott Laboratories Corporation. As advancements in drug delivery technology continue to evolve, Walsh's work will undoubtedly play a significant role in shaping the future of pharmaceuticals.